Skip to main content

Advertisement

Table 1 Summary of the 14 randomized clinical trials included in the meta-analysis on the short-term effect of fenofibrate on CRP.

From: Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials

Index Country First author and publication year Dose (mg/day) Duration (weeks) Sample size Population Randomized?
1 Korea Kim et al., 2006 [40] 200 8 54 Patients with a triglyceride level > 200 mg/dL Yes (Control group is general measures with low-calorie and low-fat diet and aerobic exercise)
2 UK Fegan et al., 2005 [17] 200 12 10 Ambulatory male or female patients aged 40-75 years with Type 2 diabetes for more than 2 years Yes (Compared with placebo)
3 Poland Undas et al. 2005 [41] 160 8 22 Patients with LDL > 130 mg/dl and triglycerides < 300 mg/dl Yes (Compared with Simvastatin)
4 Slovenia Sebestjen et al., 2004 [42] 250 12 38 Healthy male volunteers, non-smokers, aged between 40 and 60 years, with combined hyperlipidemia Yes (Compared with cerivastatin)
5 Taiwan Wang et al.,2003 [43] 200 8 35 Triglyceride between 200 and 500 mg/dl, cholesterol > 200 mg/dl, and cholesterol/HDL ratio > 5 Yes (Compared with Simvastatin)
6 Korea Wi et al., 2010 [15] 160 8 80 Patients with triglyceride levels of 150-499 mg/dL, HDL levels < 45 mg/dL and LDL levels < 130 mg/dL Yes (Compared with niacin)
7 Porland Krysiak et al., 2010 [44] 200 12 61 Metabolic syndrome with pre-diabetes Yes (Compared with placebo)
8 Porland Krysiak et al., 2010 [44] 200 12 19 Metabolic syndrome without pre-diabetes Yes (Compared with placebo)
9 USA-MI Rosenson et al., 2010 [45] 160 12 25 Patients with the metabolic syndrome Yes (Compared with placebo)
10 USA-TX Belfort et al. 2010 [46] 200 12 16 Nondiabetic insulin-resistant MetS subjects Yes (Compared with placebo)
11 Poland Pruski et al., 2009 [24] 267 8 30 Type 2 diabetic patients with mixed dyslipidemia Yes (Compared with placebo)
12 USA-UT Muhlestein et al., 2006 [13] 160 12 100 Patients with type 2 diabetes, mixed dyslipidemia and no history of coronary heart disease Yes (Compared with Simvastatin)
13 Poland Okopien et al., 2006 [32] 267 4 31 Patients with impaired glucose tolerance Yes (Compared with placebo)
14 Canada Hogue et al., 2008 [18] 200 6 19 Type 2 diabetes mellitus subjects with hypertriglyceridemia Yes (Compared with atorvastatin)